VJHemOnc Podcast
Myeloma 2022: day one highlights
Jul 27, 2022
Leading experts in the field of myeloma, Keith Stewart and Gareth Morgan, share highlights from day one of the Myeloma 2022 meeting. They discuss updates in measurable residual disease (MRD) and prognosis, antibody therapy for amyloidosis, new drugs, immune system drugs, single cell sequencing, and the potential of genomics in myeloma and cancer treatment.
11:53
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Peripheral blood MRD testing using mass spectrometry can accurately predict long-term outcomes and guide therapy adjustments in myeloma treatment.
- Immunogenic cell death and reprogramming macrophages with chimeric antigen receptors show promise as novel approaches for targeting amyloid deposits in amyloidosis treatment.
Deep dives
Peripheral Blood MRD and Mass Spectrometry vs. Whole Genome Sequencing
The podcast highlights the significance of peripheral blood minimal residual disease (MRD) in myeloma treatment. Mass spectrometry is projected to emerge as a prevailing diagnostic tool, offering high sensitivity in peripheral blood testing. It can accurately predict long-term outcomes and guide therapy adjustments. Additionally, the session discusses the utility of whole genome scanning, although its sensitivity is anticipated to be inferior to mass spectrometry. Furthermore, it explores the potential of antibody therapy and amyloidosis treatment through distinguishing tumor clones from regenerating clones and exploring novel protein forms.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
